Skip to Content

iCo Therapeutics iCo-009 (Oral Amphotericin B) Published in Leading Drug Delivery Journal

VANCOUVER, March 17, 2008 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased  to announce that iCo-009 has been highlighted in a leading drug delivery  journal, Advanced Drug Delivery Reviews. The paper discusses the development  of a novel oral Amphotericin B (AmpB) formulation ("iCo-009") with significant  antifungal activity, minimal kidney toxicity, and enhanced oral absorption of  AmpB.      

The publication, "Enhanced drug absorption using lipids: A case study  presenting the development and pharmacological evaluation of a novel  lipid-based oral Amphotericin B formulation for the treatment of systemic  fungal infections", provides further detail on the potential mechanisms by  which oral iCo-009 knocks down fungal infections.      

Publication highlights:   

-   iCo-009 significantly decreased (95%) organ fungal concentration of Aspergillus fumigatus compared to controls in the brain and the spleen, two organs where Aspergillus fumigatus typically localizes in this animal model.      
-   iCo-009 shows enhanced gastrointestinal tract absorption, plasma concentration, and tissue distribution.      
-   iCo-009 shows minimal renal toxicity.      
-   iCo-009 significantly decreased plasma galactomannan antigen levels. Detection of galactomannan in the blood can be used to diagnose Aspergillus fumigatus infections in humans.          

"iCo continues to be impressed by the work of Drs. Kishor & Ellen Wasan,"  stated Andrew Rae, President & CEO of iCo Therapeutics. "Their work continues  to improve upon the iCo-009 formulation represented in the paper, with newer  formulations showing even more dramatic anti-fungal activity and  bioavailability. iCo-009 has the potential to treat not just systemic fungal  infections, but also parasitical diseases such as Leishmaniasis in the  developing world. iCo remains very committed to UBC's global access policy and  we look forward to proceeding with development in both markets."      

iCo has an option agreement with The University of British Columbia (UBC)  for iCo-009's development, which also represents a new drug delivery  technology with the potential to reprofile other IV administered drugs to the  oral route of administration. iCo plans to develop iCo-009 under the 505(b)(2)  section of the Federal Food, Drug, and Cosmetic Act, which expressly permits  the FDA to reference safety data not developed by the applicant for approval  of a New Drug Application (NDA).   


The paper is available in the March 17, 2008 edition of Advanced Drug  Delivery Reviews. K. Sachs-Barrable, S. Lee, E. Wasan, S. Thornton, K. Wasan.  Advanced Drug Delivery Reviews 60 (2008) 692-701.   

About iCo Therapeutics   

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on  redosing or reformulating drugs with clinical history for new or expanded  indications. iCo has exclusive worldwide rights to two products, iCo-007, in  Phase I for the treatment of Diabetic Macular Edema, and iCo-008, a product  with Phase II clinical history to be developed for severe ocular allergies.  iCo Therapeutics also has an exclusive option to license iCo-009, a oral  reformulation of Amphotericin B for sight and life-threatening diseases.  iCo- 009 also represents a new drug delivery technology with the potential to  reprofile other IV administered drugs to the oral route of administration.  iCo Therapeutics trades on the TSX-Venture exchange under the symbol  "ICO".      

For more information, visit the company website at:   

No regulatory authority has approved or disapproved the content of this  release. The TSX Venture Exchange does not accept responsibility for the  adequacy or accuracy of this release.   

Forward Looking Statements   

Certain statements included in this press release may be considered  forward-looking. Such statements involve known and unknown risks,  uncertainties and other factors that may cause actual results, performance or  achievements to be materially different from those implied by such statements,  and therefore these statements should not be read as guarantees of future  performance or results. All forward-looking statements are based on iCo  Therapeutics' current beliefs as well as assumptions made by and information  currently available to iCo Therapeutics and relate to, among other things,  anticipated financial performance, business prospects, strategies, regulatory  developments, market acceptance and future commitments. Readers are cautioned  not to place undue reliance on these forward-looking statements, which speak  only as of the date of this press release. Due to risks and uncertainties,  including the risks and uncertainties identified by iCo Therapeutics in its  public securities filings; actual events may differ materially from current  expectations. iCo Therapeutics disclaims any intention or obligation to update  or revise any forward-looking statements, whether as a result of new  information, future events or otherwise.   

For further information: Business Development Contact: Dr. John Clement,  CT&DO, (778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414  x 224; Investor/Media Contact: Frederica Bell, Corporate Development, (604)  602-9414 x 228/


Posted: March 2008